Search Results for keywords:"section 529 FD

The Federal Bureau of Investigation (FBI)'s Criminal Justice Information Services (CJIS) Division announced its intent to submit a request for an information collection regarding the FBI Expungement and Sealing Form (FD-1114) to the Office of Management and Budget (OMB). This request is intended to ensure information accuracy within the FBI's systems and is required by federal regulations. The public has until April 28, 2025, to provide comments on the proposed collection. The information collection targets state, local, tribal, and federal governments, with an estimated 147,610 respondents and a total annual burden of 8,611 hours.

The Food and Drug Administration (FDA) has issued an order permanently banning Jerrod Nichols Smith from providing services related to drug product applications. This decision follows his conviction on multiple felony counts of mail fraud and obstruction of justice, connected with the unlawful distribution and misrepresentation of prescription drugs. Smith's company, Cumberland Distribution, was involved in distributing drugs illegally obtained from unlicensed sources, leading to significant profit from falsified documents and drug mislabeling. After being notified, Smith did not respond or request a hearing, resulting in his debarment which prohibits him from engaging in drug product services.

The Food and Drug Administration (FDA) announced the user fee rates for fiscal year 2025 under the Over-the-Counter (OTC) Monograph Drug User Fee Program. This program allows the FDA to collect fees from manufacturers of OTC monograph drugs, which do not require a new drug application. For FY 2025, the fee for facilities manufacturing these drugs is set at $37,556 for monograph drug facilities and $25,037 for contract manufacturing organizations. These fees help the FDA cover the costs associated with regulating OTC monograph drugs.

The Food and Drug Administration (FDA) has issued an order permanently banning John Warrington Kosolcharoen from working with companies that have approved or pending drug product applications. This decision resulted from his felony conviction for fraudulently selling an unapproved stem cell product, ReGen, and making misleading claims about its safety and effectiveness. Mr. Kosolcharoen was given the chance to challenge the debarment but did not respond in the provided timeframe, leading to a waiver of his right to a hearing on the decision. During his debarment, any business that employs him for related services could also face penalties.

The Food and Drug Administration (FDA) issued an order banning Jonathan Corbett Cosie from importing any drugs into the United States for 10 years. This decision follows his conviction for two federal felonies related to selling misbranded, unapproved drugs, including some that were falsely labeled and sold without a prescription. Mr. Cosie was notified of his debarment and given the opportunity to request a hearing, but he did not respond, waiving his right to contest the decision. The ban is effective as of March 13, 2025.

The Surface Transportation Board reviewed a petition from the Seven County Infrastructure Coalition to build an 85-mile railway in Utah to connect the Uinta Basin with the national rail network. The Coalition seeks an exemption from the usual prior approval requirements, arguing that the rail line will provide critical transportation benefits and support local industries. While there is significant support, including endorsements from state officials, there is also opposition citing financial viability concerns and potential environmental impacts. The Board has made a preliminary decision on the transportation merits but will only finalize its decision after completing an environmental review.

The Food and Drug Administration (FDA) has issued a final order denying Bernardo Garmendia's request for a hearing and has permanently banned him from providing services related to drug products. This decision stems from Garmendia's conviction for conspiracy to commit wire fraud while working at AMB Research Center, where he was involved in falsifying clinical trial documents. As of March 14, 2025, using Garmendia’s services in any drug application process incurs civil penalties for involved parties. This ruling highlights the FDA's commitment to safeguarding drug development processes.

The Food and Drug Administration (FDA) has proposed a new rule that would require most packaged foods to display a front-of-package (FOP) nutrition label called the Nutrition Info box. This label aims to help consumers quickly find and better understand important nutrition information by providing easy-to-read details about saturated fat, sodium, and added sugars. The new rule also includes updates to regulations for low sodium and low saturated fat claims, and would allow businesses time to adjust, with compliance dates varying based on their annual sales.

American Services Rail, LLC (ASR), a noncarrier, has submitted a notice to lease and operate a small rail line in Mississippi currently operated by Chicago, Rock Island & Pacific Railroad, LLC (CRIP). The arrangement allows ASR to function as a common carrier on a specific section and as a contract carrier on additional tracks. ASR affirms that no interchange commitments are involved and that the transaction will not lead to it becoming a larger rail carrier. The transaction is set to take effect on April 9, 2025, with legal precautions in place if any misleading information is found.

North Florida Industrial Railroad, LLC (NFIR) has submitted a notice to lease and operate approximately 4,891 feet of inactive railroad track in Columbia County, Florida. This track connects the North Florida Mega Industrial Park with a rail line run by Florida Gulf & Atlantic Railroad. The lease will help the park's tenants by facilitating the shipment of goods. NFIR states that its projected revenues will remain under $5 million and that this arrangement will not affect its status as a Class III rail carrier. This plan is exempt from environmental and historic preservation reviews.